How Many People Work at BioMarin Pharmaceutical? Headcount and Employee Trends

• BioMarin Pharmaceutical Inc. specializes in developing and commercializing innovative biopharmaceuticals for rare genetic diseases, positioning itself as a leader in this niche market with a total revenue of $3.2 billion in 2025, reflecting a 13% year-over-year growth.
• In December 2025, BioMarin announced a definitive agreement to acquire Amicus Therapeutics for approximately $4.8 billion, a strategic move aimed at diversifying its revenue streams and enhancing its portfolio with therapies for lysosomal storage disorders.
• The company's key products include VOXZOGO for dwarfism and the recently acquired Galafold for Fabry disease, with a focus on addressing unmet medical needs in rare diseases, which has attracted partnerships and collaborations within the biopharmaceutical sector.
• BioMarin's ideal buyers are healthcare providers and institutions specializing in rare disease treatment, as they seek innovative therapies that address significant patient needs, making it crucial for sales teams to engage with them amid the company's expanding product offerings and recent acquisitions.

BioMarin Pharmaceutical operates with a streamlined departmental structure, comprising two primary departments. The Executive department is staffed by one individual, reflecting a top-heavy leadership model. The other department, also with a headcount of one, indicates a minimal functional mix, suggesting a highly specialized operational focus within the organization.

The company's workforce is concentrated in a single location, Novato, CA, which employs one individual. The presence of 'Other' locations also accounts for one employee, indicating limited geographic distribution. This concentration suggests a centralized operational strategy, with a focus on localized talent rather than a distributed workforce.